Author: David Balderson, Sciformix – A Covance Company
Although PV starts during clinical development, it is not limited to clinical trials alone as post-market surveillance is crucial to monitoring a drug’s safety after it has been approved.
There are a range of challenges that the pharmaceutical industry faces when establishing and maintaining increasingly complex PV systems. The evolving regulatory environment in a progressively global industry places ever-more stringent demands on pharmaceutical companies to manage PV activities more efficiently than before.
Technological advances are playing a major role in pharmaceutical PV strategy updates. More companies are looking towards automation in the form of cloud-based solutions, mobile applications, robotic automation, artificial intelligence (AI) and big data analytics as a vital part of clinical, safety and regulatory operations in the pharmaceutical industry.